| Secondary |
| Product Used For Unknown Indication |
43.0% |
| Drug Use For Unknown Indication |
39.2% |
| Hiv Infection |
9.5% |
| Herpes Zoster |
1.9% |
| Rheumatoid Arthritis |
1.9% |
| Antiretroviral Therapy |
1.3% |
| Blood Cholesterol Increased |
1.3% |
| Foetal Exposure During Pregnancy |
1.3% |
| Blood Cholesterol |
0.6% |
|
| Breast Cancer In Situ |
15.0% |
| Tinnitus |
15.0% |
| Mania |
10.0% |
| Toxicity To Various Agents |
10.0% |
| Vomiting |
10.0% |
| Drug Hypersensitivity |
5.0% |
| Injection Site Reaction |
5.0% |
| Neuropathy Peripheral |
5.0% |
| Pain In Extremity |
5.0% |
| Poor Quality Drug Administered |
5.0% |
| Visual Acuity Reduced |
5.0% |
| Vitamin B6 Deficiency |
5.0% |
| Weight Decreased |
5.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
35.4% |
| Drug Use For Unknown Indication |
20.2% |
| Prophylaxis |
6.1% |
| Supplementation Therapy |
5.4% |
| Hypertension |
4.2% |
| Pain |
3.2% |
| Vitamin Supplementation |
3.1% |
| Diabetes Mellitus |
2.4% |
| Medical Diet |
2.3% |
| Breast Cancer |
2.2% |
| Osteoporosis |
2.0% |
| Multiple Myeloma |
1.9% |
| Prostate Cancer |
1.7% |
| Multiple Sclerosis |
1.6% |
| Chronic Obstructive Pulmonary Disease |
1.5% |
| Depression |
1.4% |
| Hypothyroidism |
1.4% |
| Blood Cholesterol Increased |
1.4% |
| Crohn's Disease |
1.4% |
| Hiv Infection |
1.4% |
|
| Weight Decreased |
21.6% |
| Weight Increased |
8.7% |
| Vomiting |
7.9% |
| Flushing |
6.6% |
| Visual Impairment |
5.4% |
| Pruritus |
5.0% |
| Pyrexia |
3.7% |
| Skin Discolouration |
3.7% |
| Urinary Tract Infection |
3.7% |
| Death |
3.3% |
| Insomnia |
3.3% |
| Paraesthesia |
3.3% |
| Pneumonia |
3.3% |
| White Blood Cell Count Decreased |
3.3% |
| Nausea |
2.9% |
| Oedema Peripheral |
2.9% |
| Pulmonary Embolism |
2.9% |
| Rash |
2.9% |
| Wound |
2.9% |
| Alopecia |
2.5% |
|
| Interacting |
| Product Used For Unknown Indication |
80.0% |
| Renal Transplant |
13.3% |
| Arthritis |
6.7% |
|
| Mobility Decreased |
25.0% |
| Neuropathy Peripheral |
25.0% |
| Pruritus Generalised |
25.0% |
| Visual Acuity Reduced |
25.0% |
|
